Herein, we speculate that BNB+PCO worked in a synergetic fashion, contrary to their individual supplementation, towards the inhibition of CETP activity and enhancing apoA-I expression, resulting in the substantial rise in HDL-C level and mitigation of the HC+HG triggered dyslipidemia. The gene discussed is APOA1; the disease is metabolic syndrome.